Company Information

Message from Top Management

We would like to convey our sincerest gratitude for your continued support.

WAKAMOTO PHARMACEUTICAL CO., LTD. started as a pioneering company for self-medication with the launch of a nutrient-rich, gastrointestinal remedy , “WAKAMOTO” medicine, in 1929. Upholding contributions to everyone’s health as our societal mission, we are developing our business in wide-ranging areas such as medicinal and healthcare-related products.

The environment surrounding the pharmaceutical industry has been undergoing major changes. In particular, the transition to an aging society with declining birthrates is accelerating in Japan as the baby-boomer generation will soon reach the age of 75 or over and enter the senior citizen demographic in 2025. Meanwhile, sustained systemic reform efforts are advancing for the National Health Insurance system, while fundamental reform of the drug pricing system is being implemented in order to reduce the medical expense burden on the nation. These changes are occurring with unprecedented speed.

We will operate our businesses in a way that fully meets the needs of all our customers and the society at large brought about by such changes in the environment.
 In pharmaceutical business terms, we will promote research, development, and sales of the medications and medical equipment an ultra-aged society needs, in the form of specialty pharma specialized in the field of ophthalmology.
 We will also contribute to the government policy of “self-medication promotion” in the healthcare sector, and engage in development and sales of OTC pharmaceuticals tailored to market needs.
 In the global segment, we will globalize our business by exporting unique and patented products, in addition to out-licensing.

Using our experience obtained from long history, we will contribute to the creation and progress of a healthy and prosperous society.
 All of us will come together as one and give our all to fulfill our corporate responsibilities to society, and to earn love and trust from everyone.
 We look forward to your continued support for WAKAMOTO PHARMACEUTICAL CO., LTD.

Profile

Trade name WAKAMOTO PHARMACEUTICAL CO., LTD.
Foundation April, 1929
President Arata Igarashi
Capital 3.395 billion yen
Business Manufacture and sale of ethical drugs and non-prescription drugs
Number of
Employees
Number of Employees 300 ( as of the end of March, 2022 )
Main Places of Business Head Office Tokyo
Branch Offices Sapporo, Sendai, Kanto, Tokyo,
Nagoya, Hiroshima, and Fukuoka
Research Laboratory Kanagawa
Plant Kanagawa
Head Office 2-2-2, Nihonbashi Honcho, Chuo-ku, Tokyo, 103-8330, Japan

Corporate profile video

History

April 1929 Incorporated a limited partnership company, "SOCIETY FOR NUTRITION AND PARENTING" in Shiba-koen Daimon, Tokyo, and launched "Wakamoto."
January 1933 Incorporated "SOCIETY FOR NUTRITION AND PARENTING CO., LTD." in Shiba-koen, Shiba-ku, Tokyo, and started manufacturing and selling a digestive, regulating, and nutritional agent, "Wakamoto."
December 1935 Changed the trade name to "WAKAMOTO HONPO SOCIETY FOR NUTRITION AND PARENTING CO., LTD."
July 1943 Changed the trade name to current "WAKAMOTO PHARMACEUTICAL CO., LTD."
May 1949 Listed on Tokyo Stock Exchange.
January 1962 Launched "Strong Wakamoto" with enrichment and enhancement of digestive enzymes, active lactobacillus, vitamin B1, vitamin B2, and nicotinic acid amide.
June 1968 Newly established Sagami Ohi Plant and a research laboratory in Oi-machi, Kanagawa.
August 1983 Launched a medicated toothpaste, "Coral." (currently "Coral ε")
September 1983 Listed on the first section of Tokyo Stock Exchange.
January 1989 Issued the 1st convertible corporate bond by secured collateral of the issue par value total amount of 4 billion yen.
May 1989 Launched a water soluble nonsteroidal anti-inflammatory ophthalmic solution, "Diclod Ophthalmic Solution 0.1%."
December 1994 Launched a lactobacillus preparation, "Wakamoto Intestinal Remedy."
November 1999 Launched the world's first thermal response gel technology applied ophthalmic solution, a therapeutic agent for glaucoma and ocular hypertension, "Rysmon TG Ophthalmic Solution."
November 2000 Launched a therapeutic agent for allergic conjunctivitis, "Zepelin Ophthalmic Solution 0.1%."
August 2002 Sagami Ohi Plant acquired environmental management systems ISO14001 certification.
November 2005 Launched a medicated toothpaste containing lactobacilli, "Avantbise."
July 2007 Launched a therapeutic agent for glaucoma and ocular hypertension, "Nipradilol Ophthalmic Solution 0.25%." (the product which first adopted an antiseptic free NP container)
December 2010 Launched an ophthalmic surgery adjuvant, "MaQaid Intravitreous Injection 40mg." (currently an ophthalmic surgery adjuvant/an ophthalmic adrenocortical hormone agent, "MaQaid Ophthalmic Injection 40mg")
April 2014 Relocated the head office to 2-2-2, Nihonbashi Honcho, Chuo-ku, Tokyo.
October 2015 Launched a supplement, "Optiaid DE."
April  2017 Launched a processed food containing lactobacilli, "Avantbise Oral Tablet."
October  2018 Launched an allegy-specific ophthalmic drug, "アレジフェンス(OTC product of ACITAZANOLAST HYDRATE OPHTHALMIC SOLUTION 0.1%)"
August  2019 Launched a food with functional claims, "Optiaid ML MACULAR."